去纤苷是什么药物？

What drug is it?

Defibrotide is a mixture of single-stranded oligonucleotides with antithrombotic and fibrinolytic effects. In October 2013, the European Commission granted marketing authorization to defibrotide under special circumstances for the treatment of severe hepatic veno-occlusive disease in patients undergoing HSCT. It is the first and only approved treatment for severe hepatic veno-occlusive disease in Europe.

In Europe, defibrotide is indicated for patients older than one month. Not indicated in patients with hypersensitivity to defibrotide or any of its excipients or concomitant use of thrombolytic therapy.

Defibrotide is an adenosine receptor agonist with multiple effects. The adenosine A1/A2 receptors of endothelial cells are involved in the regulation of endothelial cells and the response of endothelial cells to injury. Defibrotide can act on these receptors to produce a variety of downstream effects.

Defibrotide can also reduce the expression of cell adhesion molecules on the surface of endothelial cells, thereby reducing the adhesion of leukocytes to vascular endothelial cells and reducing the inflammatory damage of endothelial cells.

Usage and dosage of defibrotide (alias: defibrotide sodium):

1. Administer defibrinoside 6.25 mg/kg every 6 hours as a 2-hour intravenous infusion.

2. The total duration of treatment is a minimum of 21 days. If the signs and symptoms of hepatic veno-occlusive disease do not resolve after 21 days. Continue treatment until resolution.

Mechanism of action: Not yet clear, it can enhance the enzymatic activity of plasmin in vitro and hydrolyze fibrin clots.

Precautions for defibrination:

(1) Bleeding: Monitor patients for bleeding. If significant bleeding occurs, withhold or discontinue defibrotide.

(2) Hypersensitivity reaction: If severe or life-threatening allergic reaction occurs, discontinue, treat according to standard medical care, and monitor until signs and symptoms resolve.

Recommended related hot articles: /newsDetail/74898.html